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ABSTRACT
BACKGROUND: N ausea and vomiting are frequ ent adverse effects of patient-
cont rolled epidural analgesia (PCEA) with opioids.
OBJECTIVE: This study was designed to assess th e ant iemetic effect of midazo-
lam added to fentanyl-ropivacain e PCEA.
METHODS: In a prospective, random ized, double-bl ind , cont rolled trial , smoking
patients with gastric cancer undergoing elective subtotal gastrectomy were evenly allo-
cated to I of 2 treatm ent gro ups ro manage postoperati ve pain: 0.2% ropivacaine mixed
with fentanyl 4 pg/rnl, and midazolam 0.2 mg/mL (test g roup) or 0 .2% ropivacaine
mixed with fentanyl 4 pg/rnl, (cont rol group). The PCEA infusion was set to deliver
4 mLlh of the stud y solut ion, with a bolus of 2 mL per demand and a IS-minute lockout
time. The incidence of postoperati ve nausea and vom iti ng (PO NY), pain intensity, seda-
tion score, usage of rescue analgesia and rescue ant iemetic, respiratory depre ssion, ur i-
nary retention, and pruritus were recorded at 2, 6, 12, 24, 48, and 72 hours afrer surgery.
Total infused volume of PCEA at 72 hours after surgery was measured.
RESULTS: A total of 60 pati ents were approached and randomi zed to treatment.
N o patients were excluded by exclusion criteria and all enrolled patients completed
this study. Incidence of nausea (7% vs 33%; P = 0.02) in th e test group was signifi-
cantl y lower than in the control g roup. The overall frequency of PONY in the test
g roup was significantly less th an that of the control g roup (7% vs 40%; P = 0.006).
In addit ion, the mean (SD) infused volume of PCEA in th e test group was signifi-
cantly lower than that in th e cont rol group <392.3 [68.9} vs 3S1.2 [49.8} mL; P =
0.0 1). However, there were no significant differences in pain intensity, usage of rescue
anriernet ics and rescue analgesics, and mild pruritus bet ween g roups. No patient
repo rted moderate or severe seda tion, respiratory depression , or hypoxem ia. In add i-
tion , there were no severe adverse events.
CONCLUSIONS: Mid azolam added to fentanyl-rop ivacaine PCEA was associ-
ated with a significant redu cti on in th e incidence of PONY compared with femanyl-
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ropivacaine alone, and a significant decrease in the amount ofPCEA administeted without
a significant increase in adverse events in these patients who underwent subtotal gastrec-
tomy. (Curr Ther Res Clin Exp. 2010;71:298-308) © 2010 Elsevier HS Journals, Inc.
KEY WORDS: fentanyl, midazolam, nausea and vomiting, epidural analgesia.
INTRODUCTION
Patient-controlled epidural analgesia (PCEA) has been used to reduce postoperative
pain after majot abdominal surgery. I A combination of local anesthetic with opioid
has been commonly used to improve the quality of pain relief in PCEA, but this treat-
ment increases postoperative nausea and vomiting (PONV) during pCEA.2 PONY
may result in electrolyte abnormalities and dehydration.t Persistent retching or vomit-
ing following surgery can put tension on suture lines, result in hematomas beneath
surgical flaps, and place the patient at risk for pulmonary aspiration of vomit. There-
fore, these have led to attempts to combine opioid and drugs such as droperidolt-' and
naloxone'' in PCEA solution in the hope of minimizing the adverse effects (AEs) of
opioids. However, continuous infusion of droperidol did not decrease PONV5 and
naloxone, an opioid antagonist, did not increase analgesia.f
A short-acting water-soluble benzodiazepine, midazolam has been reported to de-
crease the incidence and severity of PONV.7-11 Midazolam has also been found to be
effective in the treatment of established PONV. 12 Midazolarn administered intrathecal-
ly12-14 or epidurally'<l? has been reported to have an analgesic effect. A prospective,
randomized, double-blind trial by Nishiyama et al16 found that adding midazolam
(10-20 mg for 12 hours) to continuous epidural infusion of bupivacaine (100 mg) for
postoperative pain provided better analgesia than bupivacaine alone without a deep
sedative effect in 80 patients (mean age, 58 years; weight, 56.5 kg). In addition,
Nishiyama et al17 conducted a second prospective, randomized study that investigated
the effects of adding midazolam to the postoperative epidural analgesia with 2 dif-
ferent doses (180 vs 90 mg) ofbupivacaine in 100 postgastrectomy patients (age, 40-
75 years). It was reported that epidural-infused midazolam (10-20 mg for 12 hours)
with bupivacaine 180 mg provided better analgesia compared with bupivacaine
alone. In a prospective, randomized, double-blind trial of 60 patients (mean age,
26.1 years; weight, 54.5 kg) who underwent spinal anesthesia for cesarean delivery,
intrathecal midazolam 1 mg (5 %) and 2 mg (5 %) added to bupivacaine appeared to
reduce PONY compared with controls (85%) during cesarean delivery.P However,
based on a search of the literature on MEDLINE (search terms: epidural analgesia,
midazolam, opioid, and postoperative nausea and vomiting; years, 1990-2009), no pub-
lished data were available for the antiemetic effect of midazolam added to opioid-local
anesthetics-based PCEA. Therefore, we hypothesized that epidural midazolam may
reduce PONY during PCEA and reduce the overall infused volume of PCEA.
The present study assessed the effect of midazolam added to fentanyl-ropivacaine
PCEA on the incidence of PONY in patients having subtotal gastrectomy. In addi-
tion, we investigated total consumed volume of PCEA, pain intensity, sedation level,
respiratory complications, and other AEs.
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PATIENTS AND METHODS
T his prospective, rand om ized , double-blind, cont rolled stu dy was approved by th e
et hics committee of Kyun gpook N ational Uni versit y H ospital , Daegu, Republic of
Korea. We included consecutive American Society of Anesthesiologi sts Physical
Status Classification I (no organic, ph ysiologi c, biochemical, or psychiatric di stur-
bance) and II (mi ld to moderate systemic d isturbance th at mayor may not be relat ed
to th e reason for surgery) smo ki ng pat ients with gas tric cancer, undergo ing elective
subto tal gas trectomy. W ritten informed consent was obtai ned from all patients. Pa-
t ient s with a history of d rug ab use, allergies co any of the drugs, prev ious PONY or
mot ion sicknes s, who had com plained of nausea or vom iting or received any anti-
emetic medication with in 24 hours before surgery, or wh o had liver or renal dysfunc-
tion were excluded.
The night before surgery, all patients were instructed on how to use the PCEA
device. No premedication was administered . The anesthetic regimen and postopera-
tive pain management were standardized in all patients. In th e operating room, pa-
tients were placed in th e siccing position and an ep idural catheter was inserted via
18-gauge Tuohy needle at the T8/T 9 interspace and was advanced 3 co 4 cm int o th e
epidura l space in a cephalad d irect ion. A standa rd test dose of lidocaine 2% with
epi nephrine 5 pg/mL was injected to rule out intrathecal or intravascular position of
th e cathe ter. Sensory block (loss of pinprick test) covering th e area of the proposed
incision was induced by inject ing 8 to 12 mL of 0.375% ropivacaine. General anes-
th esia was induced with propofol (2 mg/kg) and rocuronium (l .0 mg/kg) and main-
tained with 66 % nitrous oxide in oxygen with a small concentrat ion (0. 5%- 0.9%) of
isoflurane, Within 30 minutes of induction , a continuous epidural infusion of 0 .375%
ropivacaine at 0.1 mL/kg/h was initiated . Lungs were mechanically vent ilated main -
tain ing an end tidal carbon dioxide concent ration of 4. 6 kPa. It is standard pract ice
to ad mi nis ter opioids during th is surgery. Ho wever, intraoperative op ioids increase
PONY incidence"; therefore, opioids were not admini ste red duri ng the present sur-
ge ry.3 An infusion of Ringer 's solurio n (l 0 mL/kg/h) was admi nistered intravenously
toge ther with 4-mg boluses of ephedrine co maintain mean arterial pressure within
20% of baseline values throu ghout surgery. At the end of surgery, glycopyrrolate 7 pg/kg
and pyridostigmine 30 Ilg /kg were administered intravenously for antagonism of
residual neuromuscular blockade and the epidural infusion of 0 .375% of ropivacaine
was stopped .
In the postanesthetic care unit , postoperative pain relief was provided by using
PCEA with a standard pump (Abbott Ambulatory Infusion Manager plus, Abbott
Laboratories , North Ch icago, Ill ino is). Patients were randomly assigned to receive
0 .2% rop ivacaine mixed with fenta nyl 4 pg/rnl. and midazolam 0.2 mg /mL (test
g roup) or 0.2% ropivacaine mixed with fentanyl 4 pg/rnl, (cont rol g roup). In the pres-
ent study, midazolam was epid urally adm inistered at a mean rate of 0.98 mg/hr. One
anesthesiolog ist, not involved in th e study, generated the randomization sequence.
Assignment was double bl ind ed with respect to treatment. Sealed , sequenced enve-
lopes for assignment were opened on arrival in the preoperating room. Another anes-
th esiolog ist , not involved in th e study, prepared the stu dy medicat ions. These study
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drugs were concealed in numbered opaque envelopes, and all study personnel and
participants were blinded to treatment assignment for the duration of the study. The
PCEA infusion was set to deliver 4 mLlhr of the study solution, with a bolus of 2 mL
per demand and a IS-minute lockout time. Based on previous reports,16.l7 midazolam
0.2 mg/mL was chosen. Therefore, the patients in this study could receive midazolam
at a rate of 0.8 to 1.6 mg/hr.
The primary end point was the incidence of PONV and secondary end points were
total consumed volume of PCEA, pain intensity, sedation level, respiratory complica-
tion, and any other AEs during PCEA. The epidural catheter was removed at 72 hours
after surgery and then total infused volume of PCEA solution for 72 hours after sur-
gery was measured. Assessment of PONV, sedation level, pain intensity, usage of
rescue antiemetic and analgesic, and any noted AEs were collected at 2, 6, 12,24,48,
and 72 hours after the end of surgery by direct questioning by a study-blinded trainee
anes thesiologist.
Nausea was defined as a subjectively unpleasant sensation associated with awareness
of the urge to vomit, while vomiting was defined as the forceful expulsion of gastric
contents from the mouth. For the purpose of data collection, retching (defined as the
same as vomiting but without expulsion of gastric contents) was considered vomiting.
A rescue antiemetic, ondansetron 4 mg IV, was administered if vomiting occurred, or
at the patient's request to treat intolerable nausea.
Sedation levels were assessed using a 4-point scale (0 = awake; 1 = mildly sedated,
easy to wake up when spoken to; 2 = moderately sedated, easy to wake up when
slightly shaken; and 3 = deeply sedated, difficult to wake up when shaken).18 Pain in-
tensity scores were measured with a visual analog scale (VAS)from a (no pain) to 10 (the
worst possible pain). If analgesia was inadequate (verbal rate score on coughing >4)
and patients ask for more analgesia, ketorolac 50 mg IV was administered as a rescue
analgesic.
Using pulse oximetry, oxygen saturation was continuously measured during PCEA.
Reduction in oxygen saturation to <92% was treated with supplemental oxygen via face
mask, and need for oxygen treatment during the postoperative period was recorded as a
minor respiratory complication. However, a patient with hypoxemia refractory to oxygen
was regarded as unacceptable in this context and the patient was excluded. In addition,
any AEs that occurred during the study were recorded.
STATISTICAL ANALYSIS
A power analysis with a pilot study revealed that a group size of 29 would be
required to detect a reduction in the incidence ofPONV from 55% to 20% (P = 0.05;
power = 0.8). Statistical analysis was performed using SPSS version 12.0 (SPSS Inc.,
Chicago, Illinois). The t test was used to compare continuous variables; when data
were not normally distributed, the Mann-Whitney U test was used. ANOVA for re-
peated measures was used to analyze over time. Categorical data were analyzed using
the contingency table analysis with the Fisher exact test and the X2 test. Categorical
variables are presented as number (%), while continuous variables are presented as
mean (SO).
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RESULTS
Sixty consecutive patients were enrolled. No patients were excluded by exclusion
criteria and all enrolled patients completed this study. There were no significant
between-group differences in regard to demographic data or duration of anesthesia
(Table I).
Table II shows the incidence of PONV and patients requiring rescue antiernet-
ics. The incidence of nausea was significantly less in the test group than that in
the control group (2 (7%} vs 10 f33%}; P = 0.02). The overall frequency of
PONV in the test group was significantly less than that in the control group
(2 (7%} vs 12 (40%}; P = 0.006). Numerically more patients in the control group
received rescue antiemetic medication, but there was no statistically significant
difference (4 (l3%} vs 0).
Table III shows sedation scores, respiratory complications, pruritus, mean consumed
PCEA volume, and rescue analgesic. There was no difference in the level of sedation
between the 2 groups. No patients developed deep sedation or hypoxemia requiring
oxygen therapy. In addition, no patients were excluded due to severe hypoxemia
refractory to oxygen. With respect to pruritus, there was no significant between-
group difference. The mean (SD) infused volume of PCEA in the test group was
significantly lower (351.2 (49 .8} ml vs 392.3 (68.9} ml.; P = 0.01). However, there
were no significant differences in the usage of rescue analgesics (2 (7 %} vs 5 (17 %})
or VAS pain score on cough during the observation period (Figure).
No patient reported moderate or severe sedation, respiratory depression, or hypox-
emia. In addition, there were no severe AEs observed during this study.
Pruritus observed in this study was relatively mild, and there were no severe AEs
in the 2 groups.
Table I. Demographic data and duration of anesthesia in smoking patients with gastric
cancer undergoingelective subtotal gastrectomy (N = 60). Data are mean (SD)
unless otherwise indicated.
Ropivacaine- Ropivacaine-
Fentanyl-Midazolam* Fentanyl!
Variable (n =30) (n =30) P
Age, y 57.6 (2.0) 58.4 (1.9) 0.12
Male/female 18/12 20/10 0.79
Height, em 164.3 (1.4) 164.0 (1.3) 0.39
Weight, kg 61.0 (2.2) 60.9 (1.7) 0.84
Duration of
anesthesia, min 256.6 (9.1) 253.0 (7.9) 0.10
*Te5t: ropivacaine 0.2% + fentanyl 4 ug/rnt, and midazolam 0.2 rng/rnt..
t Control: ropivacaine 0.2% + fentanyl 4 ug/rnl..
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Table II. Postoperative nausea and vomiting (PONV) and requirement of rescue anti-
emetics in smoking patients with gastric cancer undergoing elective subtotal
gastrectomy (N =60). Data are number (%) of patients.
Ropivaca ine- Ropivacaine-
Fentanyl- Midazolam* Fentanylt
Variable (n = 30) (n = 30) P
PONV
0-2 h
Nausea only 2 (7) 4 (13) 0.67
Vomiti ng 0 0
2-6 h
Nausea only 0 4 (13) 0.11
Vomiting 0 0
6- 12 h
Nausea only 0 3 (10) 0.23
Vomiting 0 2 (7) 0.4 9
12- 24 h
Nausea only 0 2 (7) 0.49
Vomiting 0 0
24-48 h
Nausea only 0 2 (7) 0.49
Vomit ing 0 0
48-72 h
Nausea only 0 0
Vomit ing 0 0
0- 72 h
None 28 (93) 18 (60) 0.006
Nausea only 2 (7) 10 (33 ) 0.02
Vomit ing 0 2 (7) 0.49
Pat ients requiring
rescue anti emetic 0 4 (13) 0.11
*Test : ropivacaine 0.2 % + fentanyl 4 ug/rnt, and midazolam 0.2 mg/mL.
t Control: ropivacaine 0.2% + fentanyl 4 ug/rnt..
DISCUSSION
The overall incidence of PONY in patients receiving midazolam- fentanyl- ropivacaine
PCEA was significantl y reduced compared with fentanyl- ropivaca ine PCEA wit hou t
increasing the occurrence of AEs in these patient s who underwent partial gastrectomy.
In add ition, the total infused volume in the test group was significantly less compared
with th at in the control group.
PONY is one of the most distressing complications after anesthesia and surgery.f
In the presem study, patients' specific surgical and anesthetic factors that mighr
modify the incidence of PONY were balanced between g roups. Opioids inc rease
PONY via st im ulating the chemoreceptor zone in the area postrerna of th e medulla.19
T herefore, the differences in the incidence of PON Y can be attributed to the study
drug . In the present study, the incidence of PON Y in th e cont rol gro up was 40%. In
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Table III . Sedation, hypoxemia, pruritus , infused volume of patient-controlled epidural
analgesia (PCEA) solution, and consumption of rescue analgesics in smoking
patients with gastric cancer undergoing elective subtotal gastrectomy (N = 60).
Ropivacaine- Ropivacaine-
Fentanyl- Midazolam* Fentanyl!
Variable (n == 30 ) (n == 30 )
Sedation level,' no. (%)
0 25 (83) 28 (93)
1 5 (17) 2 (7)
2 0 0
3 0 0
Hypoxemia requiring
oxygen treatment 0 0
Hypoxemia refractory
to oxygen 0 0
Pruritus, no. (%) 8 (27) 14 (47)
Infused volume of PCEA,
mean (SO), mL 351.2 (49.8) 392 .3 (68.9)
Rescue analgesia, no. (%) 2 (7) 5 (17)
p
0.42
0 .18
0.01
0.42
*Test: ropivacaine 0.2% + fentanyl 4 ug/rnt, and midazolam 0.2 mg/mt.,
t Control: ropivacaine 0.2% + fent anyl 4 ug/rnt.
TSedation level: 0 =awake; 1 =mildly sedated, easy to wake up when spoken to; 2 =moderately sedated ,
easy to wake up when slightly shaken; 3 = deeply sedated, difficult to wake up when shaken.
th e present study, th e inciden ce of PONV in the test g roup was significantly less than
that in the control group.
The antiemetic effect of midazolam has been demonstrated with various object s of
study and various methods of ad rninisrration.Z"! ' Di Flori o and Goucke" conducted a
prospective, randomized , double-blind study in 20 patients (aged 18-82 years) with
persistent PONY refractory ro other conventional ant iemet ics comparing the ant i-
emetic effect of midazolam bol us (1 rng) followed by infusion of 1 mg/hr with pla-
cebo . It was reported that cumulative nausea score (26 vs 50; P = 0.04), vomi ting
frequency (10% vs 70%; P = 0.02), and the use of rescue antiemetic (0% vs 70 %;
P = 0.003 ) were significantly less in the midazolam group than those in placebo.
San jay and Tauro" conducted a prospective, random ized, doub le-blind trial , comparing
efficacy of midazolam versus ondanserro n, in 200 patie nts (mean age, 61 years; weight,
68 kg) on the incidence of PONY for 24 hours after cardiac surgery. A 6% incidence of
PONY was observed in patients receiving midazolam in a dose of 0.02 mg/kg/hr after
1 mg bolus compared with a 21 % incidence rate in patients receiving ondansetron
0.1 mg/kg IV every 6 hours (P < 0.001).
The exact mechanism by whi ch midazolam exerts its antiemetic act ion is not fully
understood . Postu lated mechanisms inclu de glycine mimetic inhibi tory effects.l ?
enhancement of the inhibitory effects of y-aminobutyric acid ,20 inhibition of dopa-
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Figure. Visual analog scale (VAS) scores of pain on coughing in smoking patients with
gastric cancer undergoing elective subtotal gastrectomy randomized to receive
ropivacaine 0.2% plus fentanyl 4 ~g/mL and midazolam 0.2 mg/mL (test) or ropi-
vacaine 0.2% plus fentanyl 4 ~g/mL (control) (N = 60).
mine release.!" and augmentation of adenosine-mediated inhibition of dopamine in
the chemoreceptor trigger zone.F'
Previous preclinical studies found a potential role of spinal benzodiazepine recep-
tors in segmental antinociceptive action of intrathecal midazolam.22,23 Goodchild et al24
suggested that intrathecal midazolam was involved in the release of an endogenous
opioid, acting at spinal delta receptors. The prospective, randomized, double-blind
trial by Tucker et aP3 found that midazolam 2 mg increased the analgesic effect of
fentanyl 10 pg without AEs when the drugs were administered together intrathecally
for labor pain (mean age, 29.7 years; weight, 68 kg). In the present study, there were
no significant between-group differences in VAS pain score when coughing. However,
total infused volume of PCEA in the test group was significantly less than that in the
control group.
It has been found that intravenous continuous infusion of midazolam in a dose of
about 1 mg/hr was effective for reducing PONV without sedative effects in patients
who received opioids for postoperative pain conrrol.s-? The prospective, randomized,
double-blind trial by U nlugenc er alII suggested that the antiemetic effect of rnidazo-
lam lasted longer than the sedative effect in 453 patients (mean age, 44 years; weight,
66 kg). In the present study, there were no additional sedative effects in patients who
received midazolam. However, a variety of midazolam doses should be investigated to
determine its antiemetic effectiveness and tolerability profile.
Intrathecal midazolam provides segmental analgesia, but conflicting experimental
studies have cast doubts on its safety. Malinovsky et al25 reported necrosis, hemor-
rhage, and other histopathologic changes in 2 of 9 spinal cords of rabbits that had
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received a single intrathecal injection of midazolam 0.3 mg. However, various other
experimental histopathologic studies have found that intrathecal midazolam does not
cause any morphologic changes in the spinal cord. 26,27 Tucker et aP2 suggested that
clinically useful doses of intrathecal midazolam 2 mg did not increase adverse neuro-
logic symptoms compared with conventional treatments. Aguilar et a128 found that
intrathecal infusion of midazolam for 13 months was tolerable for reducing chronic
lower back pain in a patient with chordoma. Borg and Krijnerr'? reported cases of long-
term (>2.5 years) administration of up to 6 mg/d of intrathecal midazolam in patients
with refractory neurogen and musculoskeletal pain. It was found that midazolam did
not cause any neurologic deficits. In the present study, rnidazolam was epidurally
administered at a mean rate of 0.98 mg/hr, which was consistent with previous
reporrs. 16,17 In addition, no patients who received epidural infusion of midazolam
showed neurotoxic effects.
The findings should be considered within the context of the limitation of the
study. The sample size of the study was relatively small. This study showed a lack
of power to detect significant differences in secondary outcomes. In addition, all
patients having a single type of surgery underwent a single type of general anesthe-
sia. Therefore, the results may not be widely applicable to patients undergoing other
procedures.
CONCLUSION
Midazolam added to fentanyl-ropivacaine PCEA was associated with a significant
reduction in the incidence of PONY compared with fentanyl-ropivacaine alone, and
a significant decrease in the amount of PCEA administered without a significant in-
crease in AEs in these patients who underwent subtotal gastrectomy.
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